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Objectives: Clinical trials of therapies for non–small cell
lung cancer (NSCLC) are increasingly requiring mandatory
tumor samples or research biopsies, both of which are po-
tential barriers to trial participation. We assessed the
impact of performance of research biopsies on the enroll-
ment of patients with advanced NSCLC in clinical trials.
Methods: The cases of patients with advanced NSCLC who
had been evaluated for clinical trials of systemic therapy at
the Princess Margaret Cancer Centre from January 2007 to
March 2015 were reviewed.
Results: Of the 55 clinical trials identiﬁed, 38 required tu-
mor samples for enrollment. Six mandated repeat biopsies,
whereas 32 permitted use of archival samples. Trial partic-
ipation was offered to 636 patients at 940 unique study
encounters, with some patients enrolling in multiple trials.
Of the patients in 549 encounters during which participation
in a therapeutic trial was offered, 60% received study
treatment. More patients received study treatment (83%
versus 55%, p < 0.0001) and study treatment was started
earlier (after 9 days versus after 16, p ¼ 0.002) when the
trial did not have a mandatory tissue sample requirement. A
similar trend was noted for trials permitting use of archival
tissue versus mandatory repeat biopsies. The most common
barriers to trial enrollment included absence of a required
biomarker (34%), withdrawal of consent (20%), deteriora-
tion or death (17%), other exclusion criteria (15%), and
insufﬁcient biopsy tissue (10%).
Conclusion: A growing number of NSCLC trials are requiring
tumor tissue for treatment eligibility, which appears to be a
signiﬁcant barrier to trial enrollment. Potential solutions
include use of available diagnostic samples (e.g., cytology
samples), development of peripheral blood assays for mo-
lecular markers, faster central laboratory testing turnaround
time, and more resources for rapid biopsy. 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Lung cancer is the most common cancer worldwide
and the leading cause of cancer deaths. An improved
understanding of the molecular basis of non–small cell
lung cancer (NSCLC), along with the development of
molecularly targeted therapies, has led to major im-
provements in disease outcomes.1 The effectiveness of
agents targeting epidermal growth factor gene (EGFR)-
mutant and anaplastic lymphoma kinase gene (ALK)-
rearranged NSCLC has been well established, and
molecular testing has become standard of care.2–4
Further studies of next-generation targeted therapies
for advanced NSCLC are ongoing.Journal of Thoracic Oncology Vol. 11 No. 1: 79-84
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sectable disease when ﬁrst seen and often are investi-
gated by using procedures such as bronchoscopic biopsy
or computed tomography–guided percutaneous needle
biopsy.5 Such diagnostic procedures yield small histo-
logic or cytologic samples that often are adequate for
diagnosis of malignancy; frequently, however, little or no
tissue remains for additional diagnostic studies. For pa-
tients who have had metastatic disease for an extended
period of time, diagnostic biopsy samples taken months
or years previously may not accurately reﬂect the cur-
rent molecular proﬁle of the patient’s disease.6
Many contemporary clinical trials of molecularly
targeted therapy for NSCLC mandate performance of
repeat research biopsies or submission of archival tumor
tissue samples for analysis.6 Although research biopsies
may not result in direct personal beneﬁt to the patient,
they may be used for integral biomarker analysis to
determine eligibility for a speciﬁc investigational therapy
because treatment activity may be improved by molec-
ular selection. Alternatively, research biopsies may be
used for future exploration of predictive biomarkers to
establish associations between molecular tumor features
and clinical outcome. Such indications for tumor analysis
apply to both repeat biopsies and analysis of archival
tissue. The tension between exposing patients to the
additional procedural risks of research biopsies for
exploratory assays with unclear direct clinical beneﬁt
has led to ethical debate. Supporters argue that explor-
atory data obtained from research biopsies are critical to
clarifying the mechanism of action of investigational
agents and guiding treatment decisions for future pa-
tients.7,8 Opponents argue that mandatory research bi-
opsies expose patients to risk with no direct clinical or
scientiﬁc beneﬁt, particularly in the setting of early
phase trials.9,10 In addition, patients may perceive harm
as a result of losing access to promising, even if un-
proven, experimental therapies if they are unable to
undergo the research biopsies that are required for
enrollment.11
Despite this ethical debate, many clinical trials of
therapies for advanced NSCLC now require mandatory
biopsies or archival tissue. In this study, we assess the
impact of mandatory tissue sample or biopsy re-
quirements on enrollment in clinical trials of therapies
for advanced NSCLC.Methods
Study design and population
We reviewed the cases of patients with advanced
NSCLC who had been evaluated for clinical trials of
systemic therapy at the Princess Margaret Cancer Centre,
a major comprehensive cancer center with a focus onclinical trials, from January 2007 to March 2015. Study
coordinators tracked patients who had been screened
for trials prospectively. The institutional research ethics
board reviewed and approved this study.
Patients screened for phase I, II, and III systemic
therapy trials were included. Patients screened for
research molecular proﬁling also were included. Those
screened only for radiation oncology, surgical or sup-
portive care trials, observational studies, and surveys
were excluded.
Objectives
The primary objective was to determine the impact of
mandatory tumor tissue requirements in clinical trials
on the proportion of patients with advanced NSCLC who
subsequently enrolled in those trials and proceeded to
receive study therapy. A secondary objective was to
determine the impact of mandatory tumor tissue re-
quirements on the time from initial consent to when a
repeat biopsy sample was obtained and study therapy
was started. Finally, we evaluated the reasons why pa-
tients screened for clinical trials were unable to proceed
to study enrollment.
Data collection
Trial characteristics, including phase and tumor tis-
sue requirement, were determined by reviewing study
protocols (by C.L. and M.S.). The prospective data
collected (by N.N., A.F., N.P.L., D.Z., M.S., T.P., C.L., and
M.S.) included patient demographics, trial outcomes
(including reasons why patients were excluded from or
did not enroll in trials), and detailed timeline informa-
tion (including time of initial consent, repeat biopsy, and
initiation of study treatment). These data were
conﬁrmed in clinical notes (by C.L. and M.S.).
Data analysis
Descriptive analysis was used to summarize trial and
patient characteristics. Fisher’s exact test, the Wilcoxon-
Mann-Whitney test, and the Kruskal-Wallis test were
performed where appropriate to test for differences
among the groups. Statistical analysis was carried out
using SAS v9.3 (Cary, NC).
Results
Trial characteristics
Overall, 55 trials were identiﬁed and included in this
analysis (Fig. 1). All trials were linked to investigational
therapy except for one molecular proﬁling study that
was not linked directly to therapy. The 54 trials with
investigational therapy included 12 phase I, six phase
I/II, 18 phase II, one phase II/III, and 17 phase III trials.
Thirty-eight trials (69%) required tumor tissue for
Table 1. Participant (N ¼ 636) demographics
Characteristic n
Median age at diagnosis (range), y 60 (range 18–89)
Female sex 346 (54%)
Ethnicity
White 416 (66%)
Asian 136 (21%)
Other 84 (13%)
Smoking status
Never 228 (36%)
Former 339 (53%)
Current 63 (10%)
55 Trials
[940 Consents]
37 Trials –
mandatory 
tissue, linked to 
treatment
[447 Consents]
6 Trials -
mandatory 
repeat biopsy
[87 Consents]
31 Trials –
repeat biopsy not 
required
[360 Consents]
17 Trials –
tissue not 
required, linked 
to treatment
[102 Consents]
1 Trial –
mandatory, 
tissue, molecular 
profiling 
[391 Consents]
Figure 1. Flow diagram of trial characteristics.
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tissue requirement. Six trials (11%) mandated repeat
biopsies (performed after patient consent for a trial-
speciﬁc biopsy had been obtained), whereas archival
samples were permitted for 32 trials. In the case of 24
trials, presence and/or conﬁrmation of a prespeciﬁed
biomarker was required for patients to receive investi-
gational treatment. Two permitted use of cytology or
ﬁne-needle aspirate samples, whereas all the remaining
trials required core needle or other surgical pathology
specimens.
Patient demographics
Trial participation was offered to 636 patients at 940
unique study encounters, with some patients screened
for multiple trials (Table 1). The patients’ median age at
diagnosis was 61 years (range 18–89 years), 54% were
female, 21% were Asian, and 36% had never been
smokers.
Trials linked to investigational treatment
In the 54 trials linked to investigational treatment,
participants were approached at 549 unique study en-
counters. There were 447 encounters for trials with
mandatory tissue sample requirements and 102 for tri-
als for which tumor tissue was not required (Table 2).
Overall, 60% of patients proceeded to receive study
treatment. Patients considering trials without mandatory
tissue sample requirements were more likely to receive
study treatment than were those considering trials with
such requirements (83% versus 55%, p < 0.0001).
Furthermore, such patients had a shorter time interval
from initial consent to start of treatment (median 9 days
versus 16 days, p ¼ 0.002, Table 2).
The 447 encounters for studies with mandatory tis-
sue sample requirements included 87 encounters for
trials requiring immediate prestudy biopsies. Archival
tissue was permitted for the remaining 360 study en-
counters (Table 2), with repeat biopsy required only ifarchival tissue was not available or not suitable for
analysis. Patients considering trials permitting use of
archival tissue were more likely to receive study treat-
ment than were those considering trials mandating
repeat biopsies (59% versus 38%, p ¼ 0.0007). Such
patients also had a shorter time interval from initial
consent to repeat biopsy than did patients who had
mandatory repeat biopsies performed (median 16 days
versus 21 days, p ¼ 0.02). Patients in trials permitting
use of archival tissue also had a shorter time interval
from initial consent to start of treatment (median 14
days versus 54 days, p < 0.001).
Trials with mandatory repeat biopsies
Six trials required mandatory repeat biopsies for in-
tegral biomarker analysis that was required before study
enrollment. The median time from consent to research
biopsy was 21 days (range 12–29 days). Of those pa-
tients who were screened, 41 (47%) had conﬁrmation of
the biomarker required for enrollment by a central lab-
oratory. However, eight of them were unable to begin the
study treatment on account of deteriorating clinical
status or the development of other exclusion criteria. For
the remaining 33 patients, the median time from consent
to initiation of study treatment was 54 days (range 25–
117 days).
Barriers to enrollment in trials
The reasons for not proceeding to study treatment
are summarized in Table 3. Of the patients involved in all
549 study encounters (trials linked to treatment), 220
(40%) were unable to proceed to study treatment. The
most common barrier to trial enrollment was absence of
the required prespeciﬁed biomarker (34%). Patients
withdrew consent in 20% of encounters or were
excluded on the basis of other exclusion criteria such as
comorbid conditions or poor performance status (15%).
Clinical deterioration or death (17%) after initial study
consent had been provided but before study therapy was
started were also frequent. Finally, 10% were excluded
Table 2. Trial treatment and time points for patients in trials with and without a mandatory tissue requirement
Characteristic
All therapeutic
trials (54 trials,
549 consents)
Tissue not
required
(17 trials,
102 consents)
Mandatory
tissue
(37 trials,
447 consents)
p
Value
Repeat
biopsy not
required
(31 trials,
360 consents)
Mandatory
repeat biopsy
(6 trials,
87 consents) p Value
Patients receiving study
treatment, n (%)
329 (60%) 85 (83%) 244 (55%) <0.0001 211 (59%) 33 (38%) 0.0007
Time from consent to repeat biopsy
n 128 1 127 N/A 59 68 0.02
Median (d) 18 19 18 16 21
IQR (d) 11–27 N/A 11–27 8–23 12–29
Range (d) 0–213 N/A 0–213 1–213 0–113
Time from consent to study treatment start
n 329 85 244 0.002 211 33 <0.001
Median (d) 15 9 16 14 54
IQR (d) 6–28 6–20 7–33 6–25 46–49
Range (d) 0–142 0–61 0–117 0–142 25–117
IQR, interquartile range.
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(archival or repeat biopsy sample).
In total, 128 repeat biopsies were performed. Only
one repeat biopsy was performed for a trial in which
tumor tissue was optional. The remaining repeat bi-
opsies were performed for trials with mandatory repeat
biopsies (n ¼ 68) or for patients who did not have suf-
ﬁcient archival tissue available (n ¼ 59). Six percent of
repeat biopsies performed for study had insufﬁcient
tissue for analysis. Complications, including pneumo-
thorax (13%) and local bleeding, were seen in 24% of
patients; however, only two patients required hospital
admission for biopsy-related complications. No patient
was excluded from trial participation because of biopsy-
related complications.
A molecular proﬁling trial was offered at 391 study
encounters to patients who had archival core biopsy or
resection samples available for analysis. Proﬁling was
successfully completed for 280 patients (72%), with at
least one targetable mutation detected in 196 (70%).Table 3. Reasons for not proceeding to study treatment
Characteristic
Mandatory tissue require
Mandatory repeat
biopsy (n ¼ 54)
Required biomarker not present 24 (45%)
Patient withdrew consent 5 (9%)
Clinical deterioration or death 8 (15%)
Other exclusion criteria 11 (20%)
Insufﬁcient tissue 5 (9%)
Other 1 (2%)Molecular proﬁling could not be performed for 85 pa-
tients (22%) because of insufﬁcient tissue for analysis,
and 10 patients (3%) died before completion of molec-
ular proﬁling. Another 16 patients had pending results at
the time of data cutoff.Discussion
The majority of the trials of therapies for advanced
NSCLC that were studied required tumor tissue for
enrollment, with substantial attrition among patients
screened for trials. Clinically important delays in
obtaining repeat biopsy samples and starting treatment
also were noted, particularly for trials with mandatory
repeat biopsies (in which patients experienced a greater
than threefold increase in time to starting study treat-
ment). Complex inclusion criteria and lengthy screening
procedures in addition to the logistic challenges of
repeat biopsies and analysis by a central laboratory
may account for the delays observed. So prolonged ament
Tissue not
required
(n ¼ 17)
Total
(N ¼ 220)
Repeat biopsy not
required (n ¼ 149)
52 (35%) — 76 (34%)
34 (23%) 4 (23%) 43 (20%)
27 (18%) 2 (12%) 37 (17%)
13 (9%) 10 (59%) 34 (15%)
17 (11%) — 22 (10%)
6 (4%) 1 (6%) 8 (4%)
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eight patients with the desired biomarker status after
mandatory repeat biopsy) from receiving study treat-
ment. Biopsy-related complications also resulted in
hospitalization of a few patients.
The consequences of mandatory tumor tissue re-
quirements in clinical trials of therapies for advanced
NSCLC with respect to accrual rates, potential time de-
lays, and patient attrition are sobering for investigators
and patients. Patient attitudes toward clinical trials12,13
and research biopsies14 have been studied as barriers
to participating in clinical trials. In addition to the chal-
lenges they face in overcoming these barriers, patients
remain at risk for clinical deterioration from progression
of their underlying lung cancer, thus making even small
delays highly detrimental. Although investigational
therapies often hold great promise of clinical beneﬁt,
clinical trials are often the only means for patients to
access costly novel therapies (e.g., T790M inhibitors, ALK
inhibitors, immune checkpoint agents) with documented
efﬁcacy.
Delays arise not only in connection with arranging
research biopsies, but also as a result of laboratory
analysis and biomarker testing turnaround time.15 Many
clinical trials, particularly industry-sponsored trials,
require centralized laboratory testing for conﬁrmation of
integral biomarkers and do not allow analysis in
accredited local laboratories. In addition, cytology and
ﬁne-needle aspirates are often deemed unsuitable for
research analysis, even though in many patients,
advanced NSCLC is diagnosed by using these techniques
and many laboratories have developed techniques for
molecular analysis of cytology specimens.
Current clinical trials, particularly those with molec-
ular selection, require repeat biopsies. Although molec-
ular selection contributes signiﬁcantly to lower trial
enrollment rates, repeat tumor sampling contributes
also. Repeat biopsy before subsequent targeted therapy
is justiﬁed in circumstances in which resistance muta-
tions may develop with prior therapy (e.g., T790M in-
hibitors). Whether analysis of archival tumor tissue is
appropriate is thus inﬂuenced by the biomarker of in-
terest that is being investigated. Although some of these
requirements may be driven by federal regulatory
agencies, inﬂexible requirements regarding tissue
acquisition and processing restrict the use of readily
available tumor tissue and increase logistic complexity.
Furthermore, there is debate over whether patients or
institutions have ownership of diagnostic tumor tissue,16
with some institutions rejecting patient requests for
release of their archival diagnostic tissue for research
purposes. The impact of such limitations is further
magniﬁed in resource-limited settings, such as public
health care systems.Potential limitations of this study include the gener-
alizability of our ﬁndings given that our study is limited
to a single quaternary referral center with an established
clinical trials program. We also do not know how many
patients may have been considered for clinical trial
participation but were never approached because of a
lack of the required archival tissue and reluctance on the
part of investigators to delay treatment to allow
obtaining additional tissue. Finally, we were not able to
evaluate the impact of tissue requirements and delays in
study enrollment and treatment on patient survival,
given the potential for inherent selection bias. The con-
straints of conducting research in a publicly funded
health care system with signiﬁcant resource limitations
may also restrict the generalizability of our ﬁndings to
jurisdictions without such resource limitations (e.g., bi-
opsy availability).
Despite these potential limitations, our study iden-
tiﬁes a need to reevaluate the role of research biopsies in
clinical trials and implement solutions that will improve
patient access to investigational treatment by addressing
mandatory tumor tissue requirements. Implementing
routine tissue banking at diagnosis, obtaining larger
diagnostic samples, and facilitating use of available
diagnostic specimens (e.g., cytology samples) for trials
may reduce the need for repeat biopsies and enhance
patient enrollment. Several studies have demonstrated
good correlation between small biopsy or cytology sam-
ples and resection specimens for molecular biomarkers
of current interest, including EGFR mutation and pro-
grammed cell death–ligand 1 gene (PD-L1) status.5,17
Development of peripheral blood assays, such as circu-
lating tumor DNA or other assays, for trials may eliminate
or reduce the need for research biopsies.6 Faster turn-
around time for centralized biomarker testing could also
mitigate delays in starting study therapy, as could greater
use of accredited local laboratory results. Finally, more
resources dedicated to tissue acquisition for research
purposes, in addition to resources for clinical diagnosis,
are needed to ensure timely access to research biopsies
and research for cancer patients.
Conclusions
A growing number of trials of therapies for advanced
NSCLC are requiring tumor tissue for treatment eligi-
bility, thus adding to the complexity of trial design as
patient selection becomes increasingly driven by molec-
ular analysis of tumor tissue. Molecular selection was the
most common cause of trial ineligibility in our study;
however, the requirement for additional tumor tissue
poses a signiﬁcant barrier to clinical trial enrollment,
with repeat biopsies, tissue acquisition, and central
biomarker testing resulting in signiﬁcant delays in initi-
ating study treatment and in patient attrition. Potential
84 Lim et al Journal of Thoracic Oncology Vol. 11 No. 1solutions include routine tissue banking at diagnosis,
facilitation of the use of available diagnostic samples for
trials, development of peripheral blood assays for trials,
faster central laboratory turnaround time or permission
for accredited local testing, andmore resources for timely
acquisition of tissue for clinical trials.
Acknowledgments
This work was supported by the Division of Medical
Oncology, Princess Margaret Cancer Centre. We would
like to thank Lisa Le, Darlene Dale, and the Princess
Margaret Cancer Registry for their assistance with this
project.
References
1. Peppercorn J, Shapira I, Collyar D, et al. Ethics of
mandatory research biopsy for correlative end points
within clinical trials in oncology. J Clin Oncol.
2010;28:2635–2640.
2. Mok TS, Wu YL, Thongprasert S, et al. Geﬁtinib or
carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med. 2009;361:947–957.
3. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus
standard chemotherapy as ﬁrst-line treatment for Eu-
ropean patients with advanced EGFR mutation-positive
non–small-cell lung cancer (EURTAC): a multicentre,
open-label, randomised phase 3 trial. Lancet Oncol.
2012;13:239–246.
4. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on
overall survival in patients with advanced non–small-cell
lung cancer harbouring ALK gene rearrangement: a retro-
spective analysis. Lancet Oncol. 2011;12:1004–1012.
5. Kitazono S, Fujiwara Y, Tsuta K, et al. Reliability of small
biopsy samples compared with resected specimens for
the determination of programmed death-ligand 1
expression in non–small-cell lung cancer. Clin Lung
Cancer. 2015;16:385–390.6. Olson EM, Lin NU, Krop IE, et al. The ethical use of
mandatory research biopsies. Nat Rev Clin Oncol.
2011;8:620–625.
7. Cannistra SA. Performance of biopsies in clinical
research. J Clin Oncol. 2007;25:1454–1455.
8. Agulnik M, Oza AM, Pond GR, et al. Impact and percep-
tions of mandatory tumor biopsies for correlative studies
in clinical trials of novel anticancer agents. J Clin Oncol.
2006;24:4801–4807.
9. Helft PR, Daugherty CK. Are we taking without giving in
return? The ethics of research-related biopsies and the
beneﬁts of clinical trial participation. J Clin Oncol.
2006;24:4793–4795.
10. El-Osta H, Hong D, Wheler J, et al. Outcomes of
research biopsies in phase I clinical trials: the M. D.
Anderson Cancer Center experience. Oncologist. 2011;16:
1292–1298.
11. Peppercorn J. Toward improved understanding of the
ethical and clinical issues surrounding mandatory
research biopsies. J Clin Oncol. 2013;31:1–2.
12. Manne S, Kashy D, Albrecht T, et al. Attitudinal barriers
to participation in oncology clinical trials: factor analysis
and correlates of barriers. Eur J Cancer Care (Engl).
2015;24:28–38.
13. Baggstrom MQ, Waqar SN, Sezhiyan AK, et al. Barriers to
enrollment in non–small cell lung cancer therapeutic
clinical trials. J Thorac Oncol. 2011;6:98–102.
14. Lemech C, Dua D, Newmark J, et al. Patients’ percep-
tions of research biopsies in phase I oncology trials.
Oncology. 2015;88:95–102.
15. Lim C, Tsao MS, Le LW, et al. Biomarker testing and time
to treatment decision in patients with advanced non–
small cell lung cancer. Ann Oncol. 2015;26:1415–1421.
16. Cheung CC, Martin BR, Asa SL. Deﬁning diagnostic tissue
in the era of personalized medicine. CMAJ. 2013;185:
135–139.
17. Shiau CJ, Babwah JP, da Cunha Santos G, et al. Sample
features associated with success rates in population-
based EGFR mutation testing. J Thorac Oncol.
2014;9:947–956.
